Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma.
Publication
, Journal Article
Maredia, H; Simkin, D; Soni, A; Loss, MJ
Published in: Int J Dermatol
May 2020
Duke Scholars
Published In
Int J Dermatol
DOI
EISSN
1365-4632
Publication Date
May 2020
Volume
59
Issue
5
Start / End Page
e141 / e142
Location
England
Related Subject Headings
- Treatment Outcome
- Skin Neoplasms
- Skin
- Porokeratosis
- Male
- Humans
- Fluorouracil
- Dermatology & Venereal Diseases
- Carcinoma, Squamous Cell
- Biopsy
Citation
APA
Chicago
ICMJE
MLA
NLM
Maredia, H., Simkin, D., Soni, A., & Loss, M. J. (2020). Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma. Int J Dermatol, 59(5), e141–e142. https://doi.org/10.1111/ijd.14701
Maredia, Hasina, Daren Simkin, Abha Soni, and Manisha J. Loss. “Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma.” Int J Dermatol 59, no. 5 (May 2020): e141–42. https://doi.org/10.1111/ijd.14701.
Maredia H, Simkin D, Soni A, Loss MJ. Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma. Int J Dermatol. 2020 May;59(5):e141–2.
Maredia, Hasina, et al. “Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma.” Int J Dermatol, vol. 59, no. 5, May 2020, pp. e141–42. Pubmed, doi:10.1111/ijd.14701.
Maredia H, Simkin D, Soni A, Loss MJ. Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma. Int J Dermatol. 2020 May;59(5):e141–e142.
Published In
Int J Dermatol
DOI
EISSN
1365-4632
Publication Date
May 2020
Volume
59
Issue
5
Start / End Page
e141 / e142
Location
England
Related Subject Headings
- Treatment Outcome
- Skin Neoplasms
- Skin
- Porokeratosis
- Male
- Humans
- Fluorouracil
- Dermatology & Venereal Diseases
- Carcinoma, Squamous Cell
- Biopsy